A study to compare the efficacy of neoadjuvant chemotherapy in locally advanced human epidermal growth factor receptor 2 overexpressing breast cancer
TCH exhibited greater pCR with tolerable adverse reactions in Her2neu overexpressing breast cancer compared to TAC regimen as NACT. Therefore, TCH regimen should be considered for node positive Her2neu overexpressing breast cancer.
Authors
- Dharmendra Singh (ORCID: https://orcid.org/0000-0001-8962-890X)
- Ashis Ranjan (ORCID: https://orcid.org/0000-0002-9368-7563)
- Amiy Arnav (ORCID: https://orcid.org/0000-0002-8844-5121)
- Nishit Ranjan (ORCID: https://orcid.org/0000-0002-3018-271X)
- Pritanjali Singh (ORCID: https://orcid.org/0000-0002-9538-8874)
Institutions
- All India Institute of Medical Sciences, Deoghar (IN)
- All India Institute of Medical Sciences (IN)
Publication Details
- Journal
- Reports of Practical Oncology & Radiotherapy
- Published
- 2025-02-19
- DOI
- https://doi.org/10.5603/rpor.104019
- Primary Topic
- Cancer Treatment and Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 0.00